Mounjaro Shortages in the UK: The Facts and Your Options

What the official record shows about UK Mounjaro supply

When NICE recommended tirzepatide for weight management in December 2024, demand across private and NHS pathways increased sharply. Eli Lilly had anticipated some of this, but manufacturing pharmaceutical-grade injectables at scale takes months of lead time that demand forecasts could not fully absorb. NHS England's guidance on weight-management injections acknowledges this trajectory and advises healthcare teams to consider supply continuity when starting new patients.

The shortages were not uniform. The 5mg and 7.5mg pens, the strengths most patients reach after their first few months, saw the most acute pressure during 2024. The 2.5mg starter pen remained comparatively available throughout most of that period. By mid-2025, Lilly had expanded manufacturing capacity, and the overall situation eased, though pockets of scarcity at individual pharmacies persist, particularly for doses in the middle of the titration schedule.

This is consistent with what happens whenever a medicine transitions from specialist-only to broader licensed use. The same pattern accompanied early Wegovy availability. It does not mean the medicine is being discontinued or that the supply chain is unsafe; it means production is catching up with a rapid increase in prescribing. You can read more about the clinical profile of tirzepatide to understand what makes it a uniquely high-demand product right now.

Which doses have been hardest to find, and why that matters clinically

Shortage impact is dose-dependent, and that has real consequences. A patient stabilised on 10mg who cannot source their usual pen faces a genuine clinical decision: wait, drop back to a lower dose, or source elsewhere. None of those options is trivial. Dropping a dose without prescriber input can affect tolerability and progress. Waiting introduces gaps in treatment that the prescriber needs to know about. And sourcing from an unverified seller carries risks that go far beyond a suboptimal pen.

The MHRA has warned publicly about counterfeit weight-loss pens circulating in the UK, and our guide to the Mounjaro shortage in the UK covers how that environment has developed and what it means for patients trying to source their medication safely. In October 2025, enforcement teams raided the first illicit domestic manufacturing site producing counterfeit tirzepatide pens, seizing approximately 20 million doses of illegally traded weight-loss medicines with an estimated street value of around £45 million. Fake pens have been found to contain insulin and other substances, a risk that is neither theoretical nor rare. You can check for the latest shortage update to see how the current picture looks for specific strengths.

If your prescribed dose is genuinely unavailable, contact your prescriber before doing anything else. A GPhC-registered prescriber can advise on whether a short hold, a dose adjustment, or a different pharmacy is the right path for your specific situation.

What to do if your dose is out of stock

The practical steps are straightforward, though they require a little patience. First, contact your prescribing pharmacy or clinic and ask them to check availability across their supplier network. A legitimate regulated pharmacy has access to the licensed UK supply chain and can often source doses that a single wholesaler reports as unavailable. Second, ask your prescriber whether a short treatment gap is clinically acceptable in your case, or whether a temporary dose adjustment makes sense. Third, if you are considering moving to a new provider, do so through the proper process, transfer patients should expect to provide evidence of their current treatment and dose, not simply restart from scratch.

Understanding whether there is currently a Mounjaro shortage for your specific dose is worth doing before assuming the worst. Some doses are readily available; it is worth asking before assuming otherwise. For context on how pricing and availability interact, the Mounjaro cost page explains what a legitimate prescription includes and why prices vary between providers.

One thing our prescribers hear regularly: people who ordered before midday on a Friday, assuming next-day delivery would cover the weekend, and found their pen hadn't arrived by Monday. Knowing your prescription provider's cut-off and delivery schedule is a practical detail that matters when a dose is time-sensitive.

How a regulated private pharmacy navigates supply pressures

At nume, medicines are sourced exclusively through the licensed UK supply chain via Eli Lilly's authorised supplier relationships. That matters during shortage periods because allocations from manufacturers go to pharmacies within the authorised supply network first. Unregulated sellers, social-media suppliers, and grey-market sources do not have access to those allocations, which is one reason why counterfeit pens appear when legitimate supply tightens.

Every order placed with our clinical team is reviewed individually before dispensing. If a particular pen is temporarily unavailable, we contact the patient directly rather than substituting without clinical input. That review process also means we can advise on the impact a shortage might have on a treatment plan and whether any adjustment is appropriate. You can verify our GPhC pharmacy registration (number 9012878) at the GPhC register, it takes thirty seconds and is the single most reliable way to confirm you are dealing with a legitimate UK pharmacy.

Supply pressures across the GLP-1 category are tracked closely by NHS England, and guidance is updated as the situation evolves. The NHS England weight-management injections page is the authoritative source for current commissioning and supply information. If you are ready to start a clinical assessment and want to understand which treatment options are currently available, start your free consultation and a prescriber will review your case the same day.